Skip to Content

Generic Lexiscan Availability

Lexiscan is a brand name of regadenoson, approved by the FDA in the following formulation(s):

LEXISCAN (regadenoson - solution;intravenous)

  • Manufacturer: ASTELLAS
    Approval date: April 10, 2008
    Strength(s): 0.4MG/5ML (0.08MG/ML) [RLD]

Has a generic version of Lexiscan been approved?

No. There is currently no therapeutically equivalent version of Lexiscan available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Lexiscan. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • N-pyrazole A2A adenosine receptor agonists
    Patent 6,403,567
    Issued: June 11, 2002
    Inventor(s): Jeff A.; Zablocki & Elfatih O.; Elzein & Venkata P.; Palle
    Assignee(s): CV Therapeutics, Inc.
    2-adenosine N-pyrazole compositions having the following formula: and methods for using the compositions as A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart.
    Patent expiration dates:
    • April 10, 2022
      ✓ 
      Patent use: METHOD FOR STIMULATING CORONOARY VASODILATION FOR PURPOSES OF IMAGING THE HEART
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
    Patent 6,642,210
    Issued: November 4, 2003
    Inventor(s): Jeff A.; Zablocki & Elfatih O.; Elzein & Venkata P.; Palle
    Assignee(s): CV Therapeutics, Inc.
    N-pyrazole substituted 2-adenosine compounds and methods for using the compounds as A2A-adenosine receptor agonists useful to stimulate mammalian coronary vasodilation for therapeutic purposes and as adjuncts in cardiological imaging.
    Patent expiration dates:
    • June 22, 2019
      ✓ 
      Patent use: METHOD FOR STIMULATING CORONOARY VASODILATION FOR PURPOSES OF IMAGING THE HEART
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • N-pyrazole A2A receptor agonists
    Patent 7,144,872
    Issued: December 5, 2006
    Inventor(s): Zablocki; Jeff A. & Elzein; Elfatih O. & Palle; Venkata & Belardinelli; Luiz
    Assignee(s): CV Therapeutics, Inc.
    This specification discloses 2-adenosine N-pyrazole compounds having the following formula: and methods for using the compounds as A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart.
    Patent expiration dates:
    • June 22, 2019
      ✓ 
      Patent use: METHOD OF MYOCARDIAL IMAGING
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • June 22, 2019
      ✓ 
      Patent use: METHOD OF PRODUCING CORONARY VASODILATION WITHOUT PERIPHERAL VASODILATION
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • June 22, 2019
      ✓ 
      Patent use: METHOD FOR STIMULATING CORONOARY VASODILATION FOR PURPOSES OF IMAGING THE HEART
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • N-pyrazole A2A receptor agonists
    Patent 7,183,264
    Issued: February 27, 2007
    Inventor(s): Zablocki; Jeff & Elzein; Elfatih O. & Palle; Venkata P. & Belardinelli; Luiz
    Assignee(s): CV Therapeutics, Inc.
    2-adenosine N-pyrazole compounds having the following formula: and methods for using the compounds as A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart are disclosed.
    Patent expiration dates:
    • June 22, 2019
      ✓ 
      Patent use: METHOD OF MYOCARDIAL IMAGING
      ✓ 
      Drug product
    • June 22, 2019
      ✓ 
      Patent use: METHOD OF PRODUCING CORONARY VASODILATION WITHOUT PERIPHERAL VASODILATION
      ✓ 
      Drug product
    • June 22, 2019
      ✓ 
      Patent use: METHOD FOR STIMULATING CORONOARY VASODILATION FOR PURPOSES OF IMAGING THE HEART
      ✓ 
      Drug product
  • Myocardial perfusion imaging method
    Patent 7,582,617
    Issued: September 1, 2009
    Inventor(s): Belardinelli; Luiz & Blackburn; Brent K. & Gao; Zhenhai
    Assignee(s): CV Therapeutics, Inc.
    The present invention provides a method for using the partial adenosine A2A receptor agonists having the following structure in myocardiological perfusion imaging.
    Patent expiration dates:
    • June 22, 2019
      ✓ 
      Patent use: A METHOD OF MYOCARDIAL PERFUSION IMAGING AND INCREASING CORONARY BLOOD FLOW
  • Use of A2A adenosine receptor agonists
    Patent 7,655,636
    Issued: February 2, 2010
    Inventor(s): Gordi; Toufigh & Olmsted; Ann Walls & Lieu; Hsiao Dee & Belardinelli; Luiz
    Assignee(s): Gilead Palo Alto, Inc.
    The present invention relates to methods for producing coronary vasodilation with little peripheral vasodilation by administering doses of a pharmaceutical composition including regadenoson, named (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-N-methylcarboxamide, — an adenosine A2A receptor agonist — to a human in an amount sufficient to increase the average coronary peak flow velocity by at least about 16.5 cm/sec.
    Patent expiration dates:
    • June 22, 2019
      ✓ 
      Patent use: METHOD FOR STIMULATING CORONOARY VASODILATION FOR PURPOSES OF IMAGING THE HEART
  • N-pyrazole A2A receptor agonists
    Patent 7,655,637
    Issued: February 2, 2010
    Inventor(s): Zablocki; Jeff A. & Elzein; Elfatih O. & Palle; Venkata & Belardinelli; Luiz
    Assignee(s): Gilead Palo Alto, Inc.
    2-adenosine N-pyrazole compounds having the following formula: wherein R1═CH2OH; R2 is hydrogen; R3 is selected from the group consisting of CO2R20; —CONR7R8 ,and aryl wherein the aryl substituent is optionally substituted with one substituent selected from the group consisting of halo, C 1-3alkyl and OR20;R4 is hydrogen; R7 is selected from hydrogen, and C1-3alkyl; R8 is hydrogen; and R20 is selected from hydrogen and methyl as well as methods for using the compositions as A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart are disclosed.
    Patent expiration dates:
    • June 22, 2019
      ✓ 
      Patent use: METHOD FOR STIMULATING CORONOARY VASODILATION FOR PURPOSES OF IMAGING THE HEART
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Myocardial perfusion imaging method
    Patent 7,683,037
    Issued: March 23, 2010
    Inventor(s): Belardinelli; Luiz
    Assignee(s): Gilead Palo Alto, Inc.
    The present invention relates to methods for myocardial imaging by administering at least one 2-adenosine N-pyrazole, 2-adenosine C-pyrazole or a combination thereof A2A adenosine receptor agonist to a human undergoing myocardial imaging. The invention also relates to methods of producing coronary vasodilation without significant peripheral vasodilation by administering at least one 2-adenosine N-pyrazole, 2-adenosine C-pyrazole or a combination thereof adenosine A2A adenosine receptor agonist to a human.
    Patent expiration dates:
    • June 22, 2019
      ✓ 
      Patent use: METHOD FOR STIMULATING CORONARY VASODILATION FOR PURPOSES OF IMAGING THE HEART
  • Use of A2A adenosine receptor agonists
    Patent 8,106,029
    Issued: January 31, 2012
    Inventor(s): Gordi; Toufigh & Olmsted; Ann Walls & Lieu; Hsiao Dee & Belardinelli; Luiz
    Assignee(s): Gilead Sciences, Inc.
    Myocardial imaging methods are provided that are accomplished by administering doses of a pharmaceutical composition comprising one or more adenosine A2A receptor agonists, in particular regadenoson, useful for, among other indications, myocardial imaging and coronary vasodilation, in an amount sufficient to achieve at least a minimal increase in average coronary peak flow velocity.
    Patent expiration dates:
    • June 22, 2019
      ✓ 
      Patent use: METHOD FOR STIMULATING CORONARY VASODILATION FOR PURPOSES OF IMAGING THE HEART
  • Process for preparing an A2A-adenosine receptor agonist and its polymorphs
    Patent 8,106,183
    Issued: January 31, 2012
    Inventor(s): Zablocki; Jeff & Elzein; Elfaith
    Assignee(s): Gilead Sciences, Inc.
    Disclosed is a synthesis suitable for large scale manufacture of an A2A-adenosine receptor agonist, and also relates to polymorphs of that compound, and to methods of isolating a specific polymorph.
    Patent expiration dates:
    • February 2, 2027
      ✓ 
      Drug substance
  • Myocardial perfusion imaging methods and compositions
    Patent 8,133,879
    Issued: March 13, 2012
    Inventor(s): Belardinelli; Luiz & Rosner; Mitchell
    Assignee(s): Gilead Sciences, Inc.
    The present disclosure provides 2-adenosine N-pyrazole compounds of structural formula shown below that are potent and selective agonists for A2A adenosine receptor, compositions comprising these compounds, and methods for using these compounds in a variety of applications including myocardial perfusion imaging methods.
    Patent expiration dates:
    • June 22, 2019
      ✓ 
      Drug product
  • Myocardial perfusion imaging method
    Patent 8,183,226
    Issued: May 22, 2012
    Inventor(s): Belardinelli; Luiz
    Assignee(s): Gilead Sciences, Inc.
    The present disclosure provides 2-adenosine N-pyrazole compounds exemplified by the structure shown below that are potent and selective agonists for A2A adenosine receptor, compositions comprising these compounds, and methods for using these compounds in a variety of applications including myocardial perfusion imaging and coronary vasodilation methods.
    Patent expiration dates:
    • June 22, 2019
      ✓ 
      Patent use: METHOD OF MYOCARDIAL IMAGING
  • Myocardial perfusion imaging methods and compositions
    Patent 8,470,801
    Issued: June 25, 2013
    Assignee(s): Gilead Sciences, Inc.
    A myocardial imaging method that is accomplished by administering one or more adenosine A2A adenosine receptor agonist to a human undergoing myocardial imaging as well as pharmaceutical compositions comprising at least one A2a receptor agonist, at least one liquid carrier, and at least one co-solvent.
    Patent expiration dates:
    • June 22, 2019
      ✓ 
      Patent use: METHOD OF MYOCARDIAL IMAGING
  • Methods of myocardial perfusion imaging
    Patent 8,536,150
    Issued: September 17, 2013
    Assignee(s): Gilead Sciences, Inc.
    The present invention provides a method of myocardial perfusion imaging using reduced doses of (1-{9-[(4S,2R,3R,5R)3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-N-methylcarboxamide.
    Patent expiration dates:
    • June 22, 2019
      ✓ 
      Patent use: METHOD OF MYOCARDIAL IMAGING
  • N-pyrazole A2A receptor agonists
    Patent 9,045,519
    Issued: June 2, 2015
    Assignee(s): Gilead Sciences, Inc.
    The present disclosure provides a process for the preparation of 2-adenosine N-pyrazole compounds exemplified by the structure shown below that are potent and selective agonists for A2A adenosine receptor, compositions comprising these compounds, and methods for using these compound to stimulate mammalian coronary vasodilatation for imaging the heart.
    Patent expiration dates:
    • June 22, 2019
      ✓ 
      Drug product
  • Process for preparing an A2A-adenosine receptor agonist and its polymorphs
    Patent 9,085,601
    Issued: July 21, 2015
    Assignee(s): Gilead Sciences, Inc.
    Disclosed is a synthesis suitable for large scale manufacture of an A2A-adenosine receptor agonist, and also relates to polymorphs of that compound, and to methods of isolating a specific polymorph.
    Patent expiration dates:
    • February 2, 2027
      ✓ 
      Drug product
  • Myocardial perfusion imaging methods and compositions
    Patent 9,289,446
    Issued: March 22, 2016
    Assignee(s): Gilead Sciences, Inc.
    A myocardial imaging method that is accomplished by administering one or more adenosine A2A adenosine receptor agonist to a human undergoing myocardial imaging as well as pharmaceutical compositions comprising at least one A2a receptor agonist, at least one liquid carrier, and at least one co-solvent.
    Patent expiration dates:
    • June 22, 2019
      ✓ 
      Patent use: METHOD OF MYOCARDIAL IMAGING
      ✓ 
      Drug product

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide